Adegramotide/nelatimotide - Sumitomo Dainippon Pharma

Drug Profile

Adegramotide/nelatimotide - Sumitomo Dainippon Pharma

Alternative Names: Adegramotide and nelatimotide; DSP-7888; Ombipepimut-S

Latest Information Update: 04 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sumitomo Dainippon Pharma
  • Developer Boston Biomedical; Kyoto Prefectural University of Medicine; Sumitomo Dainippon Pharma; Wakayama Medical University
  • Class Antineoplastics; Peptide vaccines
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Brain cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma; Glioma; Myelodysplastic syndromes; Soft tissue sarcoma
  • Phase I Haematological malignancies; Pancreatic cancer; Solid tumours

Most Recent Events

  • 14 Dec 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (Intradermal) (NCT03311334)
  • 30 Oct 2017 Phase-II clinical trials in Glioblastoma (Combination therapy, Recurrent) in Canada (Intradermal), Japan (Intradermal) (Sumitomo Dainippon Pharma pipeline, November 2017)
  • 23 Oct 2017 Boston Biomedical plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in November 2017 (NCT03311334)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top